InvestSMART

Australian Clinical Labs Limited (ASX:ACL)

ALERT: Price-sensitive ASX Announcement for ACL
Current share price for ACL : $2.210 -0.21 (-8.68%)+
Announcement
Release
16 Feb 2026 9:22AM
Price at Release
$2.420
Full Release
download
Summary
Australian Clinical Labs Limited announced that their Group CEO and Executive Director, Melinda McGrath, will not be renewing her contract after its conclusion on 30 August 2026. Over the past decade, Melinda has been instrumental in ACL's growth, including leading its IPO on the ASX in 2021. The company has commenced a comprehensive recruitment process to find a successor, and further updates will be provided in due time.
Key Points
  • Melinda McGrath, Group CEO and Executive Director of Australian Clinical Labs, will not renew her contract after 30 August 2026.
  • Melinda has contributed significantly to ACL's growth over the past 10 years.
  • Melinda played a key role in the company's IPO on the ASX in 2021.
  • An extensive recruitment process for a new CEO is underway.
  • The announcement was authorized for release by the Board of ACL.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.